Imikhiqizo

Umthelela oseceleni ongalindelekile wezigaba ezithile zama-anticoagulants kube yi-osteoporosis okungenzeka, okungenani ngokwengxenye, ihlobane nomsebenzi we-mesenchymal stem cell (MSC) ongasebenzi.Inhloso yocwaningo lwamanje kwakuwukuqhathanisa umphumela we-fondaparinux (FDP), inoveli ye-antithrombotic ene-heparin yesisindo se-molecular esetshenziswa kabanzi ephansi, i-tinzaparin (TZP) ekwandeni nokuhlukaniswa kwe-MSC.Ama-MSC ahlukaniswa nethambo le-trabecular leziguli ezihlukumezekile ze-14 ngenqubo yokugaya esekelwe ku-collagenase futhi yandiswa ezimweni ezijwayelekile kuze kube yilapho isigaba sesi-3. Ukwanda nokuhlukaniswa kwama-MSC kuya kuma-chondrocytes nama-osteoblasts kwahlolwa noma ngaphandle kokwengezwa kwe-FDP ne-TZP kusetshenziswa invitro evamile. izivivinyo kanye nohlu olubanzi lokugxila kwezidakamizwa.I-Flow cytometry yasetshenziselwa i-MSC phenotyping.Eqeqebeni elifundwayo lobudala (iminyaka engu-17-74 ubudala) imvamisa ye-MSC kumafrakshini akhishwe yi-collagenase yayingamaseli angama-641/10 (6) (ububanzi be-110-2,158) futhi izici zabo zokukhula zaziyizinsuku ezingu-∼4/inani labantu eliphindwe kabili.Amasiko abene-MSC phenotype ejwayelekile (CD73+, CD105+, CD146+, CD106+, ne-CD166+).Ukwanda kwamaseli kwahlolwa yikho kokubili ukuhlolwa kwe-coloni-forming unit-fibroblast (CFU-F) kanye nokuhlolwa kwe-colorimetric tetrazolium kasawoti XTT.Kuzo zombili izivivinyo, ukwanda kwe-MSC kwavinjwa ukwengezwa kwe-TZP, ikakhulukazi ekugxilweni okuphezulu.Ngokuphambene, i-FDP ayizange ibe nomthelela ekwandeni kwe-MSC.Ukuhlukaniswa kwe-Osteogenic nokuhlukaniswa kwe-chondroogenic akuzange kuthinteke ngokungezwa kwe-TZP noma i-FDP.Nakuba ukwanda kwe-MSC, kodwa hhayi ukuhlukaniswa, kuthintwa kabi yi-TZP, abukho ubufakazi bemiphumela emibi ye-FDP kulolu hlelo lwemodeli ye-in vitro ephikisana kahle ngokusetshenziswa kwayo esimweni samathambo.